Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats.

Bi LQ, Zhu R, Kong H, Wu SL, Li N, Zuo XR, Zhou SM, Kou JP, Yu BY, Wang H, Xie WP.

Int Immunopharmacol. 2013 May;16(1):7-16. doi: 10.1016/j.intimp.2013.03.010. Epub 2013 Mar 26.

PMID:
23538027
2.

Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.

Mawatari E, Hongo M, Sakai A, Terasawa F, Takahashi M, Yazaki Y, Kinoshita O, Ikeda U.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):594-600.

PMID:
17581214
3.

Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.

Zhu R, Bi L, Kong H, Xie W, Hong Y, Wang H.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12169-76. eCollection 2015.

4.

Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.

Li XL, Guan RJ, Li JJ.

J Cardiovasc Pharmacol. 2012 Aug;60(2):219-26. doi: 10.1097/FJC.0b013e31825cce63.

PMID:
22592772
5.

Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats.

Wang Q, Zuo XR, Wang YY, Xie WP, Wang H, Zhang M.

Vascul Pharmacol. 2013 Jan;58(1-2):71-7. doi: 10.1016/j.vph.2012.07.006. Epub 2012 Jul 28.

PMID:
22846229
6.

Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-κB.

Sun Q, Chen L, Gao M, Jiang W, Shao F, Li J, Wang J, Kou J, Yu B.

Int Immunopharmacol. 2012 Jan;12(1):88-93. doi: 10.1016/j.intimp.2011.10.018. Epub 2011 Nov 8.

PMID:
22079591
7.

Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.

Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.

Cardiovasc Res. 2013 Jul 1;99(1):35-43. doi: 10.1093/cvr/cvt105. Epub 2013 Apr 30.

PMID:
23631839
8.

Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.

Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH, Gewitz MH, Mathew R.

Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1250-9. doi: 10.1152/ajplung.00069.2007. Epub 2008 Apr 4.

9.

Bortezomib alleviates experimental pulmonary arterial hypertension.

Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, Lee YS.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):698-708. doi: 10.1165/rcmb.2011-0331OC. Epub 2012 Jul 27.

PMID:
22842494
10.

Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.

Li H, Lu W, Cai WW, Wang PJ, Zhang N, Yu CP, Wang DL, Liu BC, Sun W.

Pulm Pharmacol Ther. 2014 Jun;28(1):17-24. doi: 10.1016/j.pupt.2013.11.003. Epub 2013 Nov 20.

PMID:
24269521
11.

Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.

Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O.

Cardiovasc Res. 2003 Dec 1;60(3):692-9.

PMID:
14659815
12.

Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.

Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, Yip HK.

Circ J. 2008 May;72(5):825-31.

14.

Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension.

Sahara M, Sata M, Morita T, Hirata Y, Nagai R.

PLoS One. 2012;7(3):e33367. doi: 10.1371/journal.pone.0033367. Epub 2012 Mar 30.

15.

A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.

Lee JH, Park BK, Oh KS, Yi KY, Lim CJ, Seo HW, Lee BH.

Int Immunopharmacol. 2016 Nov;40:196-202. doi: 10.1016/j.intimp.2016.09.002. Epub 2016 Sep 6.

PMID:
27611861
16.

Iptakalim attenuates hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.

Zhu R, Bi LQ, Wu SL, Li L, Kong H, Xie WP, Wang H, Meng ZL.

Mol Med Rep. 2015 Aug;12(2):2945-52. doi: 10.3892/mmr.2015.3695. Epub 2015 Apr 28.

PMID:
25936382
17.

Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats.

Hongo M, Mawatari E, Sakai A, Ruan Z, Koizumi T, Terasawa F, Yazaki Y, Kinoshita O, Ikeda U, Shibamoto T.

J Cardiovasc Pharmacol. 2005 Oct;46(4):452-8.

PMID:
16160596
18.

Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension.

Lee FY, Lu HI, Zhen YY, Leu S, Chen YL, Tsai TH, Chung SY, Chua S, Sheu JJ, Hsu SY, Chang HW, Sun CK, Yip HK.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):372-84. doi: 10.1016/j.ejps.2013.08.004. Epub 2013 Aug 15.

PMID:
23954457
19.

Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.

Ding M, Lei J, Qu Y, Zhang H, Xin W, Ma F, Liu S, Li Z, Jin F, Fu E.

J Cardiovasc Pharmacol. 2015 Jun;65(6):562-70. doi: 10.1097/FJC.0000000000000224. Erratum in: J Cardiovasc Pharmacol. 2015 Sep;66(3):322. J Cardiovasc Pharmacol. 2015 Nov;66(5):514.

20.

Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats.

Sun CK, Yuen CM, Kao YH, Chang LT, Chua S, Sheu JJ, Yen CH, Ko SF, Yip HK.

Circ J. 2009 Sep;73(9):1722-30. Epub 2009 Jul 15.

Supplemental Content

Support Center